In a phase I study evaluating ZW25 safety and efficacy in patients with advanced solid tumors expressing HER2, there were 9 response-evaluable GC patients who had progressed from prior trastuzumab containing chemotherapy (NCT02892123). Here, ERBB2 is linked to gastric cancer.